Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comprehensive cytoreductive treatment after triplet/doublet conversion therapy in high-tumor-burden mHSPC
ChiCTR2400094624Phase 2Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Dec 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of goserelin, leuprolide, degarelix, abiraterone, enzalutamide and 2 more in prostate cancer (PCa), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: radiographic progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
goserelinleuprolidedegarelixabirateroneenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400094624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094624.